Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Harmony Biosciences Holdings (HRMY) EBT Margin (2020 - 2025)

Historic EBT Margin for Harmony Biosciences Holdings (HRMY) over the last 6 years, with Q3 2025 value amounting to 28.18%.

  • Harmony Biosciences Holdings' EBT Margin fell 52300.0% to 28.18% in Q3 2025 from the same period last year, while for Sep 2025 it was 27.9%, marking a year-over-year increase of 21900.0%. This contributed to the annual value of 26.84% for FY2024, which is 29600.0% down from last year.
  • According to the latest figures from Q3 2025, Harmony Biosciences Holdings' EBT Margin is 28.18%, which was down 52300.0% from 24.76% recorded in Q2 2025.
  • Harmony Biosciences Holdings' 5-year EBT Margin high stood at 34.37% for Q4 2022, and its period low was 13.03% during Q3 2021.
  • Moreover, its 5-year median value for EBT Margin was 27.41% (2022), whereas its average is 23.98%.
  • Per our database at Business Quant, Harmony Biosciences Holdings' EBT Margin surged by 2070300bps in 2021 and then crashed by -203000bps in 2024.
  • Quarter analysis of 5 years shows Harmony Biosciences Holdings' EBT Margin stood at 26.83% in 2021, then increased by 28bps to 34.37% in 2022, then tumbled by -31bps to 23.57% in 2023, then rose by 18bps to 27.9% in 2024, then rose by 1bps to 28.18% in 2025.
  • Its EBT Margin stands at 28.18% for Q3 2025, versus 24.76% for Q2 2025 and 30.95% for Q1 2025.